NKTR Dividend: Nektar Therapeutics Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

NKTR Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	62	98	90	92	101	152
Revenue Growth (YoY)	-33%	9%	-2%	-9%	-34%	33%
Cost of Revenue	7	30	33	21	24	19
Gross Profit	54	67	56	70	77	133
Selling, General & Admin	74	76	77	92	122	104
Research & Development	116	120	114	218	400	408
Operating Expenses	190	197	191	310	523	513
Other Non Operating Income (Expenses)	0	0	-6	0	-24	--
Pretax Income	-113	-119	-276	-365	-523	-443
Income Tax Expense	0	0	0	3	0	0
Net Income	-120	-118	-276	-368	-523	-444
Net Income Growth	-28.99%	-56.99%	-25%	-30%	18%	1%
Shares Outstanding (Diluted)	18.94	13.71	12.66	12.47	12.21	11.9
Shares Change (YoY)	36%	8%	2%	2%	3%	2%
EPS (Diluted)	-6.37	-8.67	-21.79	-29.51	-42.86	-37.32
EPS Growth	-47%	-60%	-26%	-31%	15%	-1%
Free Cash Flow	-190	-177	-193	-309	-427	-320
Free Cash Flow Per Share	-10.02	-12.9	-15.23	-24.76	-34.94	-26.87
Gross Margin	87.09%	68.36%	62.22%	76.08%	76.23%	87.5%
Operating Margin	-219.35%	-131.63%	-150%	-260.86%	-441.58%	-249.34%
Profit Margin	-193.54%	-120.4%	-306.66%	-400%	-517.82%	-292.1%
Free Cash Flow Margin	-306.45%	-180.61%	-214.44%	-335.86%	-422.77%	-210.52%
EBITDA	-135	-125	-128	-227	-432	-365
EBITDA Margin	-217.74%	-127.55%	-142.22%	-246.73%	-427.72%	-240.13%
D&A For EBITDA	1	4	7	13	14	14
EBIT	-136	-129	-135	-240	-446	-379
EBIT Margin	-219.35%	-131.63%	-150%	-260.86%	-441.58%	-249.34%
Effective Tax Rate	0%	0%	0%	-0.82%	0%	0%